Citadel Advisors
CDAK

Citadel Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Citadel Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-700
Closed -$122 – 15760
2023
Q1 		$122 Sell
700
-3,400
-83% -$1.89K ﹤0.01% 14576
2022
Q4 		$1.63K Sell
4,100
-9,100
-69% -$5.99K ﹤0.01% 14443
2022
Q3 		$10K Buy
13,200
+2,600
+25% +$5.46K ﹤0.01% 12288
2022
Q2 		$31K Buy
+10,600
New +$37.2K ﹤0.01% 12216

Citadel Advisors's CDAK Position: Q2 2023 in Review

Citadel Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 12,740 shares — an estimated $2.22K sold.

Citadel Advisors first reported a position in CDAK in Q1 2022 and held it in 3 quarters. The position peaked at $201K in Q1 2022. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Citadel Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 12,740 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $2.22K.
  • Citadel Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Citadel Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $201K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.